Advertisement
LT-NS001 is a prodrug, which is converted in the bloodstream intonaproxen, a non-steroidal anti-inflammatory drug (NSAID). Naproxen is widelyregarded as the NSAID with the most favorable cardiovascular safety profileamong all of the drugs in this class. In pre-clinical studies in rats anddogs, LT-NS001 was shown to cause significantly less damage to thegastrointestinal tract than equivalent doses of naproxen. LT-NS001 hascompleted pre-clinical toxicology testing and was previously evaluated in aPhase 1a randomized controlled single-dose and multiple-dose study and shownto be well tolerated.
Advertisement
"The robust pre-clinical data package for LT-NS001 suggests that thisnovel compound will provide patients with a drug that combines the efficacyand cardiovascular safety of naproxen while substantially decreasing the riskfor gastrointestinal ulceration," said Dr. Mitchell Fink, the President andCEO of Logical Therapeutics, Inc. "The results from our recently completed P1bstudy of LT-NS001 are very encouraging, because they show that administrationof the pro-drug leads to clinically useful circulating levels of naproxen."
Physicians and patients have accumulated more than 30 years of experiencewith naproxen, which is widely prescribed to treat pain and other signs andsymptoms of inflammation caused by chronic conditions, such as osteoarthritisand rheumatoid arthritis. Despite its considerable efficacy and its goodcardiovascular safety profile, naproxen, like most NSAIDs, can cause serious,even life-threatening, gastrointestinal complications. A safer alternativewould fulfill a significant unmet medical need.
The company expects to begin enrolling subjects in its next clinical studyof LT-NS001 later this year.
About Logical Therapeutics Inc.
Logical Therapeutics, Inc. is a privately held biotechnology company basedin Waltham, Massachusetts. Logical Therapeutics is developing drugs to treata variety of medical conditions that are associated with excessiveinflammation, including osteoarthritis and rheumatoid arthritis. For moreinformation on Logical Therapeutics, visit the company's website atwww.logicaltherapeutics.com or send an email to [email protected]
SOURCE Logical Therapeutics, Inc.
